Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer

Inclusion Criteria: * Willing and able to understand and sign an informed consent form (ICF) for the study approved by the Investigator's local or a central Institutional Review Board (IRB) * Have recently diagnosed, pathologically confirmed, non-metastatic SCC of the oral cavity, oropharynx, hypopharynx, or larynx that will be treated with ChemoRT as first-line treatment; subjects with a history of surgical management are eligible * Have a plan to receive a continuous course of conventional external beam irradiation delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0 to 2.2 Gy, with a cumulative radiation dose between 50 and 72 Gy. Planned radiation treatment fields must include at least 2 oral sites (buccal mucosa, floor of oral cavity, tongue, or soft palate), with each site receiving ≥ 50 Gy * Have a plan to receive a standard cisplatin CT regimen administered tri-weekly (80 to 100 mg/m2, on Days 0, 21, and 42) or weekly (30 to 40 mg/m2) * Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Have adequate hematopoietic, hepatic, and renal function at the screening visit: * Hematopoietic function * Hemoglobin ≥ 10 g/dL * Absolute neutrophil counts (ANC) ≥ 1,500 cells/mm3 * Platelet count ≥ 100 × 109/L * Hepatic function * Total bilirubin \< 1.5 times the upper-normal limit (ULN) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.0 times the ULN * Renal function: Serum creatinine concentration ≤ 2 mg/dL; if result is ≥ 1.4 mg/dL and ≤ 2.0 mg/dL, a 24-hour urinary creatinine clearance test must be performed by the site's local laboratory. To be eligible for the study, a subject must demonstrate a 24-hour urinary creatinine clearance ≥ 50 mL/min * Have a negative serum pregnancy test if a woman is of childbearing potential * Agree to use medically acceptable methods of birth control during study participation and for 30 days following the last CTM treatment if a woman is of childbearing potential * Males or females aged 18 years or older. Exclusion Criteria: * Tumor of the lips, sinuses, salivary glands, nasopharynx, or unknown primary tumor * Metastatic disease (M1) Stage IV C * Prior radiation to the head and neck * Plan to be treated with cetuximab (Erbitux®) * Have undergone induction CT * History of other malignant tumors, excluding non-melanoma skin cancer or curatively excised in situ cervical carcinoma * Have had a major surgical procedure, other than for HNC, or significant traumatic injury within 4 weeks prior to the initiation of RT; anticipation of need for a major surgical procedure during the study * Active infectious disease, excluding oral candidiasis * Have OM at the baseline visit * Have a diagnosis of autoimmune disease requiring chronic immunosuppression * Known seropositivity for HIV, HBV, or HCV * Prior use of SCV 07 * Have used any investigational agent within 30 days of randomization * Are pregnant or breastfeeding * Known allergies or intolerance to cisplatin * Unable to give informed consent or comply with study requirements, including completing the subject diary and QOL instruments * Have any other condition or therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with follow-up visits.